摘要
目的:观察坦索罗辛联合非那雄胺对老年前列腺增生症患者的下尿路症状和IPSS评分的影响。方法:选取老年前列腺增生症患者96例,随机分为观察组和对照组各48例。观察组采用坦索罗辛联合非那雄胺口服进行治疗,对照组单纯口服非那雄胺进行治疗。治疗3个月后,对比两组患者的临床疗效,治疗前后的国际前列腺症状评分(IPSS)、最大尿流率、膀胱残余尿量和前列腺体积的变化情况。同时观察两组患者治疗过程中的不良反应发生情况。结果:观察组治疗后的有效率为83.33%,显著高于对照组(P<0.05);观察组治疗后的IPSS评分为(9.47±5.08)分,膀胱残余尿量为(32.38±12.42)mL,对照组的IPSS评分为(13.16±3.52)分,膀胱残余尿量为(33.59±10.47)mL,均显著低于治疗前(P<0.05);观察组的最大尿流率为(13.86±4.68)mL/s,对照组的最大尿流率为(11.02±3.86)mL/s,均显著高于治疗前(P<0.05)。观察组治疗后的IPSS评分显著低于对照组,而最大尿流率显著高于对照组(P<0.05)。两组患者治疗过程中均未发生明显的不良反应。结论:坦索罗辛联合非那雄胺治疗老年前列腺增生症具有良好的临床疗效,可改善患者的临床症状且安全性高,值得进一步推广应用。
Objective: To observe the efficacy of combination of tamsulosin and finasteride on urinary symptoms and IPSS score for elderly patients with benign prostatic hyperplasia( BPH). Method: 96 elderly patients with BPH were selected and randomly divided into observation group and control group,with 48 cases in each group. Subjects in observation group were treated with tamsulosin combined with finasteride,while subjects in control group were treated with finasteride only. After 3 months of treatment,the clinical efficacy,International Prostate Symptom Score( IPSS),changes of maximum flow rate,residual urine volume and prostate volume of the two groups were compared. The adverse reaction of the two groups was recorded.Result: The effective rate of the observation group was 83.33%,which was significantly higher than that in the control group( P〈0.05). After the treatment,the IPSS score of the observation group was( 9.47 ± 5.08)and the residual urine volume was( 32.38 ± 12.42) mL. While in the control group,the IPSS score was(13.16 ± 3.52),and residual urine volume was( 33.59 ± 10.47) mL. The IPSS score and residual urine volume of the two groups were significantly lower than those before therapy( all P〈0.05). The maximum flow rate of the observation group and the control group was( 13.86 ± 4.68) mL /s and( 11.02 ± 3.86) mL /s,which were significantly higher than those before the treatment( P 0.05). After the treatment,the IPSS score of the observation group was significantly lower than the control group,while the maximum urinary flow rate was significantly higher than the control group( P〈0.05). No obvious adverse reaction of the two groups were happened. Conclusion: Combination of tamsulosin and finasteride has good clinical efficacy in elderly patients with benign prostate hyperplasia. It can improve clinical symptoms,and it is safe. It is worthy of further application.
出处
《河北医学》
CAS
2014年第8期1246-1249,共4页
Hebei Medicine
基金
重庆市科研课题
(编号:2011-2-504)
关键词
前列腺增生症
老年
非那雄胺
坦索罗辛
Benign prostatic hyperplasia
Elderly patients
Finasteride
Tamsulosin